Developer docs
API playgroundTry for free, no card

Search company profiles

Sanegene Bio

Full company profile

uuid0000c28

Namestring
Sanegene Bio
Legal namestring
SanegeneBio
Websiteurl
sanegenebio.com
Company typeenum
Private
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWoburn, United States
HQ citystring
Woburn
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNAi therapeutics, gene silencing medicines, obesity therapeutics, complement-mediated diseases, RNAi drug discovery
Industry4 codes
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
RNAi Therapeutics / Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Upfront payments, development and commercialization milestone payments, and tiered royalties on future product sales from licensing agreements with pharmaceutical partners.

prnewswire.com
2Strategic Partnerships and Co-development
TypeLicensing Royalties
Description

Revenue from co-development arrangements including cost-sharing, milestone payments, and potential royalty streams from partner-funded clinical development programs.

sanegenebio.com
3Equity Financing
TypeData Monetisation
Description

Series B financing of over $110 million raised from institutional investors, strategic investors, and existing shareholders to fund R&D operations and clinical development.

sanegenebio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

SanegeneBio develops RNAi-based therapeutics that silence disease-causing genes, with a clinical pipeline targeting obesity and metabolic disorders, complement-mediated autoimmune diseases (IgA nephropathy, C3 glomerulopathy, PNH, aHUS), and cardiovascular diseases (hypertension, dyslipidemia, cardiomyopathy). The company's candidates leverage the proprietary LEAD™ delivery platform for tissue-selective gene silencing in liver and extrahepatic tissues, including adipocytes, skeletal muscle, and immune cells, with potential for bi-annual subcutaneous dosing. Revenue is generated through out-licensing and co-development partnerships with Eli Lilly, Genentech/Roche, and Innovent Biologics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • SGB-9768 achieved 96.3% maximum reduction in serum C3 levels and 100% inhibition of alternative pathway activity maintained through Week 24 in Phase 1
+2 more records
Product overview1 text field

SanegeneBio is a clinical-stage biotech developing a diversified pipeline of RNAi-based therapeutics for metabolic/obesity, cardiovascular, and autoimmune diseases. The portfolio is powered by the proprietary LEAD™ (Ligand and Enhancer Assisted Delivery) platform enabling tissue-selective delivery to liver, adipose, muscle, and immune cells. Core clinical programs include SGB-7342 (INHBE, obesity), SGB-9768 (C3, complement-mediated diseases), and SGB-3908 (AGT, hypertension, partnered with Innovent). The company has multiple preclinical and clinical-stage candidates spanning obesity, dyslipidemia, cardiomyopathy, and coagulopathies.

Product and service12 records
1LEAD™ (Ligand and Enhancer Assisted Delivery) Platform
CategoryDrug Delivery Technology Platform
Description

Proprietary tissue-selective RNAi delivery technology that enables targeted gene silencing in liver, adipose tissue, skeletal muscle, and immune cells through novel receptor-mediated internalization mechanisms. Supports bi-annual subcutaneous dosing potential with a GalNAc-like safety profile, and is the core enabling platform for SanegeneBio's pipeline of RNAi therapeutic candidates.

2SGB-7342
CategoryClinical Stage RNAi Therapeutic - Obesity
Description

GalNAc-conjugated siRNA therapeutic targeting INHBE (Inhibin Beta E) mRNA in hepatocytes for the treatment of obesity. Designed to reduce circulating Activin E levels and improve metabolic abnormalities while preserving lean muscle mass, addressing limitations of GLP-1 therapies.

3SGB-9768
CategoryClinical Stage RNAi Therapeutic - Complement-Mediated Diseases
Description

GalNAc-conjugated siRNA therapeutic targeting complement C3 mRNA in hepatocytes for complement-mediated kidney and hematologic diseases including IgA Nephropathy (IgAN), C3 Glomerulopathy (C3G), IC-MPGN, Paroxysmal Nocturnal Hemoglobinuria (PNH), and atypical Hemolytic Uremic Syndrome (aHUS). Demonstrated best-in-class potential with 96.3% maximum reduction in serum C3 levels and 100% inhibition of alternative pathway activity.

4SGB-3908
CategoryClinical Stage RNAi Therapeutic - Hypertension
Description

GalNAc-conjugated siRNA therapeutic targeting angiotensinogen (AGT) mRNA for the treatment of hypertension, jointly developed with Innovent Biologics (Innovent designation: IBI3016). Demonstrated sustained AGT mRNA reduction with potential for biannual dosing.

5SGB-3383
CategoryPipeline RNAi Therapeutic - Complement-Mediated Diseases
Description

siRNA therapeutic targeting complement factor B (CFB) in the liver for complement-mediated diseases including atypical Hemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH). SanegeneBio retains global commercial rights.

6SGB-BS01
CategoryPipeline RNAi Therapeutic - Cardiovascular
Description

siRNA therapeutic targeting PCSK9 and ANGPTL3 in the liver for dyslipidemia. SanegeneBio retains global commercial rights.

7SGB-BS02
CategoryPipeline RNAi Therapeutic - Cardiovascular
Description

siRNA therapeutic targeting PCSK9 and LPA in the liver for dyslipidemia. SanegeneBio retains global commercial rights.

8SGB-CV01
CategoryPipeline RNAi Therapeutic - Cardiovascular
Description

siRNA therapeutic targeting an undisclosed gene in the heart for cardiomyopathy. SanegeneBio retains global commercial rights.

9SGB-OB03
CategoryPipeline RNAi Therapeutic - Obesity
Description

siRNA therapeutic targeting an undisclosed gene in adipose tissue for obesity. SanegeneBio retains global commercial rights.

10SGB-OB04
CategoryPipeline RNAi Therapeutic - Obesity
Description

siRNA therapeutic targeting ACVR2 in skeletal muscle for obesity and other indications. SanegeneBio retains global commercial rights.

11SGB-3252
CategoryPipeline RNAi Therapeutic - Coagulopathies
Description

siRNA therapeutic targeting PLG in the liver for coagulopathies including Hereditary Hemorrhagic Telangiectasia (HHT) and Heavy Menstrual Bleeding (HMB). SanegeneBio retains global commercial rights.

12SGB-IM03
CategoryPipeline RNAi Therapeutic - Immunology
Description

siRNA therapeutic targeting MST1 in the liver for COPD and other immune conditions. SanegeneBio retains global commercial rights.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-02-02
Description

Global licensing agreement for one of SanegeneBio's RNAi programs using LEAD™ platform targeting metabolic and autoimmune conditions. SanegeneBio receives $200 million upfront and eligible for up to $1.5 billion in development and commercialization milestones plus tiered royalties. Genentech leads all future clinical development and worldwide commercialization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-10
Description

Joint development partnership for SGB-3908 (IBI3016), an siRNA targeting angiotensinogen for hypertension treatment. Phase 1 data presented at AHA 2025. Innovent and SanegeneBio collaborating on clinical development with Innovent conducting Phase 2 and 3 trials in Asia while SanegeneBio handles Phase 3 globally.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-11-08
Description

Global research and licensing collaboration for RNAi therapeutics targeting metabolic diseases using SanegeneBio's LEAD™ platform. SanegeneBio responsible for discovery and identification of optimized LEAD™-based RNAi molecules; Lilly handles IND-enabling studies, clinical development and commercialization. Deal includes upfront payment, equity investment, near-term milestones, and potential milestones up to $1.2 billion plus tiered royalties.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2023-01-01
Description

Partnership to identify tissue-specific delivery mechanisms for RNA therapeutics through hit identification and cell-based internalization studies, expanding SanegeneBio's delivery capabilities.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Wave is a clinical-stage genetic medicines company developing stereopure oligonucleotide therapeutics including siRNA and other modalities. Comparable to Sanegene in stage and oligonucleotide chemistry focus, with overlapping targets in metabolic and rare diseases via partnerships with GSK and Takeda.

TypeOthers
Description

Innovent is a leading Chinese biopharmaceutical company that is both a strategic partner to Sanegene (co-developing SGB-3908 for hypertension in Asia) and an adjacent comparator as a China-based clinical-stage biologics developer. While not an RNAi competitor, it is a relevant ecosystem participant and commercialization partner.

TypeDirect peer
Description

Rona Therapeutics is a clinical-stage Chinese RNAi company developing siRNA therapeutics for metabolic and rare diseases, founded by ex-Sanofi and ex-Alnylam executives. Closely comparable to Sanegene in target indications (obesity, complement), modality, and stage, and competes in the same China-led RNAi development ecosystem.

TypeRegional player
Description

Sirnaomics is a clinical-stage RNAi therapeutics company headquartered in Maryland with R&D operations in China, developing siRNA candidates for oncology and fibrosis. Highly comparable to Sanegene in cross-border US-China biotech structure, oligonucleotide modality, and clinical-stage profile, making it a regional/structural peer.

TypeBroad incumbent
Description

Novartis, through its partnership with Alnylam on Leqvio (inclisiran, an siRNA targeting PCSK9) and its own oligonucleotide programs, is a broad incumbent in the siRNA cardiovascular space. Directly comparable to Sanegene's PCSK9/ANGPTL3 dyslipidemia programs and represents the type of large-pharma commercialization infrastructure Sanegene aspires to access.

TypeDirect peer
Description

Arrowhead is a clinical-stage RNAi therapeutics company developing multiple TRiM-enabled siRNA programs across metabolic, cardiovascular, and rare disease indications. Closely comparable to Sanegene in stage, modality (GalNAc-conjugated siRNA), and indication focus, with a similar partnership-driven business model (Amgen, Takeda, GSK, Sanofi).

TypeEmerging player
Description

Viridian is a clinical-stage biopharmaceutical company developing siRNA and antibody therapies for autoimmune and rare diseases. While its current lead programs are antibody-based (anti-IGF-1R, anti-FcRn), its emerging RNAi interest and metabolic disease focus make it a partially overlapping emerging peer.

TypeDirect peer
Description

Silence Therapeutics is a clinical-stage RNAi company developing GalNAc-conjugated siRNA therapies for cardiovascular and hematologic diseases. Its SLN360 (Lp(a)) and SLN124 (TMPRSS6) programs overlap directly with Sanegene's cardiovascular and complement pipelines, making it a closely matched direct peer in technology and stage.

TypeBroad incumbent
Description

Alnylam is the leading commercial-stage RNAi therapeutics company with multiple FDA-approved siRNA drugs (Onpattro, Givlaari, Oxlumo, Amvuttra, Leqvio via partnership). It is the dominant player in GalNAc-conjugated liver RNAi and serves as both a direct technology comparable and the primary competitive benchmark for Sanegene's siRNA pipeline.

TypeBroad incumbent
Description

Dicerna was a clinical-stage RNAi company acquired by Novo Nordisk in 2021 for $3.3B; its GalXC RNAi platform is now integral to Novo's oligonucleotide pipeline in cardiometabolic and rare diseases. As a former pure-play RNAi competitor now embedded in a major pharma, it represents the strategic exit template most relevant to Sanegene.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors24 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sanegene Bio

RNAi Therapeutics / Biopharmaceuticalssanegenebio.com

Sanegene Bio firmographics

Firmographics
Name
Sanegene Bio
Legal name
SanegeneBio
Website
https://sanegenebio.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Sanegene Bio industry classification

Industry
Product category
RNAi Therapeutics / Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • RNAi therapeutics
  • Gene silencing medicines
  • Obesity therapeutics
  • Complement-mediated diseases
  • RNAi drug discovery

Where Sanegene Bio is headquartered

Location

Headquarters

HQ city
Woburn
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Sanegene Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing and Milestone Payments: Upfront payments, development and commercialization milestone payments, and tiered royalties on future product sales from licensing agreements with pharmaceutical partners.
  2. Strategic Partnerships and Co-development: Revenue from co-development arrangements including cost-sharing, milestone payments, and potential royalty streams from partner-funded clinical development programs.
  3. Equity Financing: Series B financing of over $110 million raised from institutional investors, strategic investors, and existing shareholders to fund R&D operations and clinical development.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Sanegene Bio product offering

Product offering

Core offering

SanegeneBio develops RNAi-based therapeutics that silence disease-causing genes, with a clinical pipeline targeting obesity and metabolic disorders, complement-mediated autoimmune diseases (IgA nephropathy, C3 glomerulopathy, PNH, aHUS), and cardiovascular diseases (hypertension, dyslipidemia, cardiomyopathy). The company's candidates leverage the proprietary LEAD™ delivery platform for tissue-selective gene silencing in liver and extrahepatic tissues, including adipocytes, skeletal muscle, and immune cells, with potential for bi-annual subcutaneous dosing. Revenue is generated through out-licensing and co-development partnerships with Eli Lilly, Genentech/Roche, and Innovent Biologics.

Product overview

SanegeneBio is a clinical-stage biotech developing a diversified pipeline of RNAi-based therapeutics for metabolic/obesity, cardiovascular, and autoimmune diseases. The portfolio is powered by the proprietary LEAD™ (Ligand and Enhancer Assisted Delivery) platform enabling tissue-selective delivery to liver, adipose, muscle, and immune cells. Core clinical programs include SGB-7342 (INHBE, obesity), SGB-9768 (C3, complement-mediated diseases), and SGB-3908 (AGT, hypertension, partnered with Innovent). The company has multiple preclinical and clinical-stage candidates spanning obesity, dyslipidemia, cardiomyopathy, and coagulopathies.

Differentiator

Problem solved

Functional benefit

Products and services

  • LEAD™ (Ligand and Enhancer Assisted Delivery) Platform Proprietary tissue-selective RNAi delivery technology that enables targeted gene silencing in liver, adipose tissue, skeletal muscle, and immune cells through novel receptor-mediated internalization mechanisms. Supports bi-annual subcutaneous dosing potential with a GalNAc-like safety profile, and is the core enabling platform for SanegeneBio's pipeline of RNAi therapeutic candidates.
  • SGB-7342 GalNAc-conjugated siRNA therapeutic targeting INHBE (Inhibin Beta E) mRNA in hepatocytes for the treatment of obesity. Designed to reduce circulating Activin E levels and improve metabolic abnormalities while preserving lean muscle mass, addressing limitations of GLP-1 therapies.
  • SGB-9768 GalNAc-conjugated siRNA therapeutic targeting complement C3 mRNA in hepatocytes for complement-mediated kidney and hematologic diseases including IgA Nephropathy (IgAN), C3 Glomerulopathy (C3G), IC-MPGN, Paroxysmal Nocturnal Hemoglobinuria (PNH), and atypical Hemolytic Uremic Syndrome (aHUS). Demonstrated best-in-class potential with 96.3% maximum reduction in serum C3 levels and 100% inhibition of alternative pathway activity.
  • SGB-3908 GalNAc-conjugated siRNA therapeutic targeting angiotensinogen (AGT) mRNA for the treatment of hypertension, jointly developed with Innovent Biologics (Innovent designation: IBI3016). Demonstrated sustained AGT mRNA reduction with potential for biannual dosing.
  • SGB-3383 siRNA therapeutic targeting complement factor B (CFB) in the liver for complement-mediated diseases including atypical Hemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH). SanegeneBio retains global commercial rights.
  • SGB-BS01 siRNA therapeutic targeting PCSK9 and ANGPTL3 in the liver for dyslipidemia. SanegeneBio retains global commercial rights.
  • SGB-BS02 siRNA therapeutic targeting PCSK9 and LPA in the liver for dyslipidemia. SanegeneBio retains global commercial rights.
  • SGB-CV01 siRNA therapeutic targeting an undisclosed gene in the heart for cardiomyopathy. SanegeneBio retains global commercial rights.
  • SGB-OB03 siRNA therapeutic targeting an undisclosed gene in adipose tissue for obesity. SanegeneBio retains global commercial rights.
  • SGB-OB04 siRNA therapeutic targeting ACVR2 in skeletal muscle for obesity and other indications. SanegeneBio retains global commercial rights.
  • SGB-3252 siRNA therapeutic targeting PLG in the liver for coagulopathies including Hereditary Hemorrhagic Telangiectasia (HHT) and Heavy Menstrual Bleeding (HMB). SanegeneBio retains global commercial rights.
  • SGB-IM03 siRNA therapeutic targeting MST1 in the liver for COPD and other immune conditions. SanegeneBio retains global commercial rights.

Quantifiable outcome

  • SGB-9768 achieved 96.3% maximum reduction in serum C3 levels and 100% inhibition of alternative pathway activity maintained through Week 24 in Phase 1
  • +2 more outcomes

Companies that use Sanegene Bio

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Sanegene Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Sanegene Bio partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered major, core and supporting.

  • Genentech (Roche Group)majorStrategic or Co-development Partner · 2 February 2026Global licensing agreement for one of SanegeneBio's RNAi programs using LEAD™ platform targeting metabolic and autoimmune conditions. SanegeneBio receives $200 million upfront and eligible for up to $1.5 billion in development and commercialization milestones plus tiered royalties. Genentech leads all future clinical development and worldwide commercialization.
  • Innovent BiologicscoreStrategic or Co-development Partner · 10 November 2025Joint development partnership for SGB-3908 (IBI3016), an siRNA targeting angiotensinogen for hypertension treatment. Phase 1 data presented at AHA 2025. Innovent and SanegeneBio collaborating on clinical development with Innovent conducting Phase 2 and 3 trials in Asia while SanegeneBio handles Phase 3 globally.
  • Eli Lilly and CompanymajorStrategic or Co-development Partner · 8 November 2025Global research and licensing collaboration for RNAi therapeutics targeting metabolic diseases using SanegeneBio's LEAD™ platform. SanegeneBio responsible for discovery and identification of optimized LEAD™-based RNAi molecules; Lilly handles IND-enabling studies, clinical development and commercialization. Deal includes upfront payment, equity investment, near-term milestones, and potential milestones up to $1.2 billion plus tiered royalties.
  • Orbit Discovery LimitedsupportingTechnology or Integration · 1 January 2023Partnership to identify tissue-specific delivery mechanisms for RNA therapeutics through hit identification and cell-based internalization studies, expanding SanegeneBio's delivery capabilities.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Sanegene Bio competitors and assessment

Company assessment

Direct peers

  • Wave Life Sciences: Wave is a clinical-stage genetic medicines company developing stereopure oligonucleotide therapeutics including siRNA and other modalities. Comparable to Sanegene in stage and oligonucleotide chemistry focus, with overlapping targets in metabolic and rare diseases via partnerships with GSK and Takeda.
  • Rona Therapeutics: Rona Therapeutics is a clinical-stage Chinese RNAi company developing siRNA therapeutics for metabolic and rare diseases, founded by ex-Sanofi and ex-Alnylam executives. Closely comparable to Sanegene in target indications (obesity, complement), modality, and stage, and competes in the same China-led RNAi development ecosystem.
  • Arrowhead Pharmaceuticals: Arrowhead is a clinical-stage RNAi therapeutics company developing multiple TRiM-enabled siRNA programs across metabolic, cardiovascular, and rare disease indications. Closely comparable to Sanegene in stage, modality (GalNAc-conjugated siRNA), and indication focus, with a similar partnership-driven business model (Amgen, Takeda, GSK, Sanofi).
  • Silence Therapeutics: Silence Therapeutics is a clinical-stage RNAi company developing GalNAc-conjugated siRNA therapies for cardiovascular and hematologic diseases. Its SLN360 (Lp(a)) and SLN124 (TMPRSS6) programs overlap directly with Sanegene's cardiovascular and complement pipelines, making it a closely matched direct peer in technology and stage.

Others

  • Innovent Biologics: Innovent is a leading Chinese biopharmaceutical company that is both a strategic partner to Sanegene (co-developing SGB-3908 for hypertension in Asia) and an adjacent comparator as a China-based clinical-stage biologics developer. While not an RNAi competitor, it is a relevant ecosystem participant and commercialization partner.

Regional players

  • Sirnaomics: Sirnaomics is a clinical-stage RNAi therapeutics company headquartered in Maryland with R&D operations in China, developing siRNA candidates for oncology and fibrosis. Highly comparable to Sanegene in cross-border US-China biotech structure, oligonucleotide modality, and clinical-stage profile, making it a regional/structural peer.

Broad incumbents

  • Arrowhead Pharma subsidiary (was) + Novartis siRNA efforts: Novartis, through its partnership with Alnylam on Leqvio (inclisiran, an siRNA targeting PCSK9) and its own oligonucleotide programs, is a broad incumbent in the siRNA cardiovascular space. Directly comparable to Sanegene's PCSK9/ANGPTL3 dyslipidemia programs and represents the type of large-pharma commercialization infrastructure Sanegene aspires to access.
  • Alnylam Pharmaceuticals: Alnylam is the leading commercial-stage RNAi therapeutics company with multiple FDA-approved siRNA drugs (Onpattro, Givlaari, Oxlumo, Amvuttra, Leqvio via partnership). It is the dominant player in GalNAc-conjugated liver RNAi and serves as both a direct technology comparable and the primary competitive benchmark for Sanegene's siRNA pipeline.
  • Dicerna Pharmaceuticals (Novo Nordisk): Dicerna was a clinical-stage RNAi company acquired by Novo Nordisk in 2021 for $3.3B; its GalXC RNAi platform is now integral to Novo's oligonucleotide pipeline in cardiometabolic and rare diseases. As a former pure-play RNAi competitor now embedded in a major pharma, it represents the strategic exit template most relevant to Sanegene.

Emerging players

  • Viridian Therapeutics: Viridian is a clinical-stage biopharmaceutical company developing siRNA and antibody therapies for autoimmune and rare diseases. While its current lead programs are antibody-based (anti-IGF-1R, anti-FcRn), its emerging RNAi interest and metabolic disease focus make it a partially overlapping emerging peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

Sanegene Bio social profiles

Digital presence

Sanegene Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sanegene Bio leadership team

Management profile

Number of profiles

Profiles9 records

Sanegene Bio funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors24 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sanegene Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanegene Bio

What does Sanegene Bio do?

SanegeneBio develops RNAi-based therapeutics that silence disease-causing genes, with a clinical pipeline targeting obesity and metabolic disorders, complement-mediated autoimmune diseases (IgA nephropathy, C3 glomerulopathy, PNH, aHUS), and cardiovascular diseases (hypertension, dyslipidemia, cardiomyopathy). The company's candidates leverage the proprietary LEAD™ delivery platform for tissue-selective gene silencing in liver and extrahepatic tissues, including adipocytes, skeletal muscle, and immune cells, with potential for bi-annual subcutaneous dosing. Revenue is generated through out-licensing and co-development partnerships with Eli Lilly, Genentech/Roche, and Innovent Biologics.

Is Sanegene Bio a public or private company?

Sanegene Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sanegene Bio founded?

Sanegene Bio was founded in 2021. It employs 11 to 50 people.

Where is Sanegene Bio based?

Sanegene Bio is headquartered in Woburn, United States, in the North America region.

How does Sanegene Bio make money?

Three revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are strategic Partnerships and Co-development and equity Financing.

Who are Sanegene Bio's main competitors?

Direct peers on record are Wave Life Sciences, Rona Therapeutics, Arrowhead Pharmaceuticals and Silence Therapeutics. Innovent Biologics is listed as an others. Sirnaomics is listed as a regional player. Broad incumbents are Arrowhead Pharma subsidiary (was) + Novartis siRNA efforts, Alnylam Pharmaceuticals and Dicerna Pharmaceuticals (Novo Nordisk). Viridian Therapeutics is listed as an emerging player.

Does Sanegene Bio have an API?

No public API is recorded for Sanegene Bio.

What industry is Sanegene Bio in?

Sanegene Bio's product category is RNAi Therapeutics / Biopharmaceuticals. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BloombergSuzhou Sanegene Bio Is Said to Target 2027 for Hong Kong ListingSanegene Bio Inc. is targeting a 2027 Hong Kong IPO after confidentially filing, working with China International Capital Corp. and Morgan Stanley. The RNA interference therapeutics company could raise a few hundred million dollars.BloombergSuzhou Sanegene Bio Is Said to Target 2027 for Hong Kong ListingSuzhou Sanegene Bio Inc. is targeting a 2027 Hong Kong IPO after confidentially filing, according to people familiar with the matter. The RNA interference therapeutics company is working with China International Capital Corp. and Morgan Stanley on an IPO that could raise a few hundred million dollars.Pharmaceutical TechnologySanegeneBio, Genentech sign $1.5bn global RNAi licensing dealSanegeneBio signed a $1.5bn global licensing deal with Genentech for an RNAi programme, granting Genentech exclusive rights. SanegeneBio receives a $200m upfront payment and milestone payments up to $1.5bn, plus tiered royalties. The company will manage early development while Genentech handles clinical and commercialization.VC News DailySanegene Bio Closes Over $110 Million Series BSanegene Bio, a biotechnology company based in Woburn, Massachusetts, has raised more than $110 million in a Series B funding round to advance its RNAi programs toward registration studies and expand development across metabolic, cardiovascular, and autoimmune diseases. The round was led by an unnamed industrial investor and joined by international sovereign fund, China Biopharma, Legend Capital, Eli Lilly, Hillhouse, Qiming, and other returning investors. This financing comes as global RNA-based medicines gain momentum and investors show renewed confidence in advanced delivery platforms.VenturecapitalSanegene Bio Secures Over $110 Million in Series B Financing for RNAi Programs and Disease DevelopmentSanegene Bio raised over $110 million in Series B financing to advance its RNAi programs and expand development across metabolic, cardiovascular, and autoimmune diseases. The funding round reflects growing investor interest in RNA-based medicines and confidence in the company's advanced delivery platforms. No specific timeline, investors, or use of funds details were disclosed in the article.pharmaphorumSanegeneBio raises $110m for RNAi, plus other financingsSanegeneBio, a Boston/Shanghai/Suzhou-based RNAi drug developer backed by Tencent, raised $110 million in a Series B round backed by Eli Lilly, weeks after signing a $1.2 billion alliance with Lilly to deploy its LEAD platform for delivering RNAi drugs to tissues outside the liver. The funding is part of a broader wave of biotech financings this week, including Sidera Bio raising DKK 700 million, D3 Bio completing a $108 million round, BlossomHill Therapeutics closing an $84 million Series B extension, and Prolynx raising $70 million in a Series A. Proceeds are earmarked for clinical programs spanning autoimmune, cardiometabolic, and oncology candidates including SanegeneBio's SGB-9768 for IgA nephropathy, D3 Bio's elisrasib as a next-generation KRAS G12C inhibitor, and Prolynx's obesity therapies with less frequent dosing.EIN PresswireAntisense & RNAi Therapeutics Market 2025-2029: Unveiling Growth Developments with the Latest UpdatesThe Business Research Company has published a market report projecting the global antisense and RNAi therapeutics market to grow from $1.75 billion in 2024 to $1.93 billion in 2025, and further to $3.11 billion by 2029, driven by a CAGR of 10.2% and 12.8% respectively. Key growth drivers include increased funding, technological advancements, rising healthcare expenditures, a growing elderly population, and heightened demand for RNA therapeutics accelerated by the COVID-19 pandemic. Notable trends include intensified R&D for rare diseases, nanoparticle applications, and strategic collaborations such as the January 2023 partnership between Orbit Discovery Limited and SanegeneBio Inc. for tissue-specific RNA therapeutics delivery.The Pharma LetterSanegene closes over $110 million series B to advance RNAi pipelineSanegene Bio has raised over $110 million in a Series B funding round to advance its RNAi programs toward registration studies and expand development across metabolic, cardiovascular, and autoimmune disease areas. The financing arrives amid growing momentum for global RNA-based medicines and renewed investor confidence in advanced delivery platforms. The capital will support the company's progression of its RNAi pipeline through key development milestones.SanegenebioSanegeneBio Raises over $110 Million in Series B FinancingSanegeneBio, a clinical-stage biotechnology company developing RNAi therapeutics, announced on December 8, 2025 the closing of a Series B financing round raising over $110 million. The round was co-led by an industrial investor with participation from multiple institutional and strategic investors including Eli Lilly and Company, sovereign wealth funds, and venture capital firms. The financing will advance the company's clinical-stage assets toward registrational studies and accelerate development programs across autoimmune, cardiovascular, metabolic, and obesity therapeutic areas using its LEAD™ RNAi delivery platform.BioPharma APACEli Lilly Partners with SanegeneBio to Advance RNAi Therapies for Metabolic DiseasesSanegeneBio and Eli Lilly have entered a global research and licensing collaboration to develop RNAi therapeutics for metabolic diseases using SanegeneBio's LEAD™ delivery platform. Under the agreement, SanegeneBio will handle discovery while Eli Lilly manages clinical development and commercialization, with potential milestone payments exceeding $1.2 billion.